Largest biotech by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech ranked by net assets, at ZAR 390.8B, ahead of BioNTech (ZAR 367.2B) and Biogen (ZAR 314.3B). Figures as of 18 Nov 2026, 14:23 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesZAR 390.8B
- Median
- ZAR 34.7B
- Combined market value
- ZAR 14.62T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | ZAR 390.8B | ZAR 3.64T | ZAR 2,930.92 | 1.60% up | 33% up | ||
| 2 | BioNTechBNTX · Health Care | ZAR 367.2B | ZAR 362.2B | ZAR 1,460.81 | 0.47% down | 16% down | ||
| 3 | BiogenBIIB · Health Care | ZAR 314.3B | ZAR 638.2B | ZAR 4,317.20 | 0.34% down | 49% up | ||
| 4 | AmgenAMGN · Health Care | ZAR 149B | ZAR 4.26T | ZAR 7,882.99 | 0.95% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | ZAR 148.9B | ZAR 1.44T | ZAR 3,559.94 | 3.93% down | 755% up | ||
| 6 | argenxARGX · Health Care | ZAR 126.1B | ZAR 1.03T | ZAR 16,310.99 | 0.36% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | ZAR 65B | ZAR 176.8B | ZAR 856.42 | 0.12% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | ZAR 56B | ZAR 289.1B | ZAR 2,856.21 | 0.37% up | 20% up | ||
| 9 | VaxcytePCVX · Health Care | ZAR 46.2B | ZAR 161.9B | ZAR 1,022.54 | 3.59% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | ZAR 37.2B | ZAR 287.7B | ZAR 1,179.19 | 2.09% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | ZAR 36.3B | ZAR 196.4B | ZAR 1,250.28 | 0.22% down | 26% up | ||
| 12 | RepligenRGEN · Health Care | ZAR 36.3B | ZAR 178.5B | ZAR 2,791.83 | 0.37% down | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | ZAR 33.1B | ZAR 67B | ZAR 691.16 | 0.54% down | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | ZAR 28.1B | ZAR 605.8B | ZAR 2,800.61 | 2.50% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | ZAR 27.2B | ZAR 178.6B | ZAR 2,091.89 | 3.44% down | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | ZAR 21B | ZAR 152.3B | ZAR 5,139.36 | 0.22% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | ZAR 14.7B | ZAR 118.3B | ZAR 571.69 | 0.21% down | 43% up | ||
| 18 | CG OncologyCGON · Health Care | ZAR 13B | ZAR 121.4B | ZAR 1,358.90 | 6.89% down | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | ZAR 8.1B | ZAR 131.4B | ZAR 1,928.01 | 6.63% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | ZAR 4.2B | ZAR 94.7B | ZAR 776.03 | 1.21% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | ZAR 3.8B | ZAR 79.4B | ZAR 490.44 | 2.22% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | ZAR 2.7B | ZAR 109B | ZAR 1,666.35 | 3.90% down | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | ZAR 840.3M | ZAR 188.4B | ZAR 1,652.07 | 0.55% down | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -ZAR 8.6B | ZAR 114.6B | ZAR 107.76 | 4.68% up | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2144 ZAR).
Questions and answers
Which biotech rank first by net assets?
Gilead Sciences (ZAR 390.8B), BioNTech (ZAR 367.2B) and Biogen (ZAR 314.3B) are the top three of the 24 biotech ranked by net assets as of 18 Nov 2026, 14:23 UTC.
How many biotech are in this ranking?
24 are ranked by net assets.
What are these biotech worth together?
The 24 biotech ranked by net assets have a combined market value of ZAR 14.62T as of 18 Nov 2026, 14:23 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.